Background: Stereotactic body radiotherapy (SBRT) and sublobar resection (SLR) are current treatment options for patients with cStage I non-small-cell lung cancer (NSCLC) who are operable, but at high risk for lobectomy. However, optimal selection of the two treatments remains controversial. Purposes of this study are to identify pre-treatment factors affecting treatment decision and to evaluate their impact on outcomes. Method: We retrospectively reviewed patients who underwent SBRT or SLR for cStage I NSCLC because of medical comorbidity between 2003 and 2009. Patients who were with performance status of 2 or worse, those who had no data on pre-treatment pulmonary function test, or those who had no histological confirmation of NSCLC were excluded. A propensity score (PS) model of treatment decision (0 toward SBRT, and 1 toward SLR) was generated using stepwise logistic regression incorporating pre-treatment factors. Result: Ninety-two and 65 patients who underwent SBRT and SLR, respectively, were enrolled into this analysis. Median potential followup period was 8.6 years. The following factors remained in the PS model after stepwise selection: age, sex, Charlson comorbidity index (CCI), body mass index (BMI), forced expiratory volume in 1 second (FEV1) and tumor diameter. Old age, male, CCI of 1 or more, underweight BMI and large tumor had coefficients toward SBRT (Table) . In a cohort with PS of 0.5 or more, overall survival was significantly better in SLR patients than in SBRT patients (79.5% and 47.5% at 5 years, respectively; P ¼ 0.004). In a cohort with PS<0.5, whereas, overall survival was similar between SLR and SBRT (43.3% and 39.7% at 5 years, respectively; P ¼ 0.805). Conclusion: The PS model would help appropriate treatment selection for high-risk operable patients. Although patients with PS of 0.5 or more benefit from SLR, SBRT provides comparable outcomes for patients with PS<0.5.
Background: Treatment of apical lung tumors with stereotactic body radiation therapy (SBRT) can be challenging due to proximity to the brachial plexus (BP). We retrospectively investigated outcomes after treatment of apical lung tumors to compare the rate of brachial plexopathy (BPX) with what would be estimated based on published protocol-derived BP constraints. Method: Apical lung tumors were defined in this analysis as those whose lung SBRT target had a planning-derived PTV edge <1cm from the anatomic BP. We surveyed an IRB-approved prospective registry of 1,462 patients treated with SBRT for the interval 2003-2017 and included all patients who received definitive or salvage SBRT using dose/fractionation schedules of 50 Gy/5 fx, 60 Gy/ 5 fx, or 48 Gy/4 fx. Salvage SBRT included patients with local recurrence after conventional fractionation radiotherapy. Per RTOG protocols, the subclavian vein (SCV) ipsilateral to target was contoured as the BP surrogate. In this study, the ipsilateral subclavian artery (SCA), and BP were also contoured to characterize dosimetric differences between structures. Statistical analysis involved repeated measures ANOVA. Result: Sixty-four patients, which includes six patients (9.4%)
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